Systems and methods for gas mixing in ocular surgical equipment
US-2019254870-A1 · Aug 22, 2019 · US
US11104885B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11104885-B2 |
| Application number | US-201916717942-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 17, 2019 |
| Priority date | Oct 11, 2013 |
| Publication date | Aug 31, 2021 |
| Grant date | Aug 31, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Methods are described for predicting ancestral sequences for viruses or portions thereof. Also described are predicted ancestral sequences for adeno-associated virus (AAV) capsid polypeptides. The disclosure also provides methods of gene transfer and methods of vaccinating subjects by administering a target antigen operably linked to the AAV capsid polypeptides.
Opening claim text (preview).
What is claimed is: 1. An adeno-associated virus (AAV) capsid polypeptide having the amino acid sequence shown in SEQ ID NO: 3. 2. The AAV capsid polypeptide of claim 1 , wherein the AAV capsid polypeptide or a virus particle comprising the AAV capsid polypeptide: exhibits a lower seroprevalence than does an AAV2 capsid polypeptide or a virus particle comprising an AAV2 capsid polypeptide, and wherein the AAV capsid polypeptide or a virus particle comprising the AAV capsid polypeptide exhibits about the same or a lower seroprevalence than does an AAV8 capsid polypeptide or a virus particle comprising an AAV8 capsid polypeptide; and/or is neutralized to a lesser extent by human serum than is an AAV2 capsid polypeptide or a virus particle comprising an AAV2 capsid polypeptide, and wherein the AAV capsid polypeptide or a virus particle comprising the AAV capsid polypeptide is neutralized to a similar or lesser extent by human serum as is an AAV8 capsid polypeptide or a virus particle comprising an AAV8 capsid polypeptide. 3. The AAV capsid polypeptide of claim 1 , wherein the AAV capsid polypeptide is purified. 4. The AAV capsid polypeptide of claim 1 encoded by the nucleic acid sequence shown in SEQ ID NO: 4. 5. A nucleic acid molecule encoding an adeno-associated virus (AAV) capsid polypeptide having the nucleic acid sequence shown in SEQ ID NO: 4. 6. A vector comprising the nucleic acid molecule of claim 5 . 7. An isolated host cell comprising the vector of claim 6 . 8. A purified virus particle comprising the AAV capsid polypeptide of claim 1 . 9. The purified virus particle of claim 8 , further comprising a transgene.
Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title
Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation · CPC title
viral genome or elements thereof as genetic vector · CPC title
Demonstrated in vivo effect · CPC title
Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.